Dokoumetzidis A - Search Results

1

Optimization of a paediatric fixed dose combination mini-tablet and dosing regimen for the first line treatment of tuberculosis.

Tsiligiannis A, Sfouni M, Nalda-Molina R, Dokoumetzidis A. Tsiligiannis A, et al. Among authors: dokoumetzidis a. Eur J Pharm Sci. 2019 Oct 1;138:105016. doi: 10.1016/j.ejps.2019.105016. Epub 2019 Jul 26. Eur J Pharm Sci. 2019. PMID: 31356869

2

Proper lumping in systems biology models.

Dokoumetzidis A, Aarons L. Dokoumetzidis A, et al. IET Syst Biol. 2009 Jan;3(1):40-51. doi: 10.1049/iet-syb:20070055. IET Syst Biol. 2009. PMID: 19154083 Free article.

3

Predictive models for oral drug absorption: from in silico methods to integrated dynamical models.

Dokoumetzidis A, Kalantzi L, Fotaki N. Dokoumetzidis A, et al. Expert Opin Drug Metab Toxicol. 2007 Aug;3(4):491-505. doi: 10.1517/17425225.3.4.491. Expert Opin Drug Metab Toxicol. 2007. PMID: 17696801 Review.

4

Fractional kinetics in drug absorption and disposition processes.

Dokoumetzidis A, Macheras P. Dokoumetzidis A, et al. J Pharmacokinet Pharmacodyn. 2009 Apr;36(2):165-78. doi: 10.1007/s10928-009-9116-x. Epub 2009 Apr 2. J Pharmacokinet Pharmacodyn. 2009. PMID: 19340400

5

Modelling and simulation in drug absorption processes.

Dokoumetzidis A, Valsami G, Macheras P. Dokoumetzidis A, et al. Xenobiotica. 2007 Oct-Nov;37(10-11):1052-65. doi: 10.1080/00498250701502114. Xenobiotica. 2007. PMID: 17968736 Review.

6

Modeling and Monte Carlo simulations in oral drug absorption.

Dokoumetzidis A, Kosmidis K, Argyrakis P, Macheras P. Dokoumetzidis A, et al. Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):200-5. doi: 10.1111/j.1742-7843.2005.pto960309.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 15733215 Free article. Review.

7

Bayesian optimal designs for pharmacokinetic models: sensitivity to uncertainty.

Dokoumetzidis A, Aarons L. Dokoumetzidis A, et al. J Biopharm Stat. 2007;17(5):851-67. doi: 10.1080/10543400701514007. J Biopharm Stat. 2007. PMID: 17885870

8

A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system.

Dokoumetzidis A, Macheras P. Dokoumetzidis A, et al. Int J Pharm. 2006 Sep 14;321(1-2):1-11. doi: 10.1016/j.ijpharm.2006.07.011. Epub 2006 Jul 15. Int J Pharm. 2006. PMID: 16920290

9

Development of a reaction-limited model of dissolution: application to official dissolution tests experiments.

Dokoumetzidis A, Papadopoulou V, Valsami G, Macheras P. Dokoumetzidis A, et al. Int J Pharm. 2008 May 1;355(1-2):114-25. doi: 10.1016/j.ijpharm.2007.11.056. Epub 2007 Dec 5. Int J Pharm. 2008. PMID: 18206324

10

The mean dissolution time depends on the dose/solubility ratio.

Rinaki E, Dokoumetzidis A, Macheras P. Rinaki E, et al. Among authors: dokoumetzidis a. Pharm Res. 2003 Mar;20(3):406-8. doi: 10.1023/a:1022652004114. Pharm Res. 2003. PMID: 12669960

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results